Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O15315
UPID:
RA51B_HUMAN
Alternative names:
RAD51 homolog B; RAD51-like protein 1
Alternative UPACC:
O15315; O60914; O75210; Q3Y4F8; Q6FHX8; Q86SY3; Q86SY4; Q86TR0; Q86U92; Q86U93; Q86U94; Q8N6H4; Q9UPL5
Background:
DNA repair protein RAD51 homolog 2, also known as RAD51 homolog B or RAD51-like protein 1, plays a crucial role in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks. It is involved in DNA replication or repair processes induced by DNA-damaging agents, promoting the assembly of RAD51 nucleoprotein filaments, and is part of the RAD51 paralog protein complex BCDX2, functioning in the BRCA1-BRCA2-dependent HR pathway.
Therapeutic significance:
Understanding the role of DNA repair protein RAD51 homolog 2 could open doors to potential therapeutic strategies.